Why can non-compliant drugs "all the way"

　　Qiushi

　　The State Drug Administration recently issued a notice on 18 batches of drugs that did not meet the requirements, involving 11 types of drugs from multiple manufacturers, of which 5 were Chinese medicines, 4 were injections for injection, and 2 were compound preparations.

Why can non-compliant drugs still circulate in the market?

Experts analyze that the problems involved in the non-compliance of drugs not only originate from the production side, but also involve transportation, storage, sales and other links. It is recommended that the entire chain of drug supervision be strengthened.

(December 17 "Economic Information Daily")

　　Since non-compliant drugs can "unblock all the way", it shows that the blocking effect of the intermediate links has not been brought into play.

This reminds us that drug supervision must not only focus on the production link, but also strengthen the supervision of the circulation and use links.

This is conducive to discovering the problems left over from the production process, thus playing a role in checking for omissions, and also discovering new problems in the circulation and use links, such as deterioration of medicines.

　　Pharmaceutical manufacturers must also strengthen their own responsibilities. In addition to ensuring that there are no quality problems in the production process, they should also implement quality supervision and restraint from the front-end to the back-end of drug production and circulation. For example, if drug quality problems are found, timely recall; for drug distribution companies Improve the requirements for transportation and storage conditions and conduct inspections; collect feedback on terminal use information; unblock the recovery channels for temporary drugs and expired drugs.

Pharmaceutical sales are not a one-shot deal, and a more comprehensive after-sales service is essential.

　　The quality supervision awareness of drug buyers such as hospitals should also be strengthened, so that quality inspections can be carried out from the back end to the front end, and problems can be found in the first time and rectification can be promoted.

For other ordinary goods, whether it is a middleman or a consumer, as long as they find quality problems, they will promptly report back and hold them accountable, and they can even demand multiple compensation.

Not only that, the general product also has established an advance compensation rule. When consumers find product quality problems, they can directly ask the seller to take responsibility without having to go to the manufacturer.

This is not only a kind of self-protection, but also a basic law of the market.

Drugs, a special product that needs more quality assurance, should strengthen the application of quality inspection rules.

　　There is a very common phenomenon in clinical practice: when patients or family members find that there are quality problems in drugs or medical devices, such as foreign bodies in the infusion tube, the first reaction of the hospital is often that the infusion tube is purchased through a regular channel and undergoes strict inspections. , Have a product certificate to prove that you are right, and believe that even if there is a mistake, it is the fault of the manufacturer and the quality supervision department.

The logic behind this is that hospitals, as the buyers of medicines, have no responsibility for quality inspection. In this context, patients, as victims, will sue the hospital or the manufacturer, which is often a dilemma.

　　Although intermediate entities such as drug distribution companies, hospitals, and pharmacies are not the end users of drugs, they are all buyers compared to upstream manufacturers.

If the buyer’s quality supervision awareness and quality inspection responsibility are strengthened, a powerful internal supervision force of the system will be mobilized, which cannot be replaced by external supervision forces.

Moreover, this supervisory force can not only be traced back to the leading manufacturers, but also can supervise each other because they have formed a trading relationship.

In this way, non-compliant drugs are easy to be discovered in time, and it is difficult to "flow smoothly" from top to bottom.